Efficacy and safety assessment of retinol palmitate (Vitamin A) for acute brain infarction, phaseI and multi-center, randomized controlled, phaseII trial.

Efficacy and safety assessment of retinol palmitate (Vitamin A) for acute brain infarction, phaseI and multi-center, randomized controlled, phaseII trial. - Efficacy and safety assessment of retinol palmitate (Vitamin A) for acute brain infarction, phaseI and multi-center, randomized controlled, phaseII trial.

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015513

Enrollment

Registered

2014-10-23

Start date

2014-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain infarction

Interventions

Group with taking retinol palmitate Group without taking retinol palmitate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Acute brain infarction patients who visit hospital within 24 hours after symptom oncet and whose NIHSS is between 3 and 15 points. 2)Patients with consent of this study in writing which obtained from patients or legal representative.

Exclusion criteria

Exclusion criteria: 1)Patients with pregnancy. 2)Patinents who take Vitamin A derivative (Etretinate/ tretinoin/ tamibarotene). 3)Patients with serious organ damage. 4)Patients who are considered inappropriate to participate in the study by principal investigator.

Design outcomes

Primary

Measure	Time frame
The ratio of equal or more than 3 points improvement of NIHSS on 30+/-4days after treatment compared with admission.	—

Secondary

Measure	Time frame
1)mRS on discharge 2)NIHSS on 7+/-1days after admission, NIHSS compared with admission. 3)NIHSS/mRS on 30+/-4days after admission, NIHSS/mRS compared with admission. 4)NIHSS/mRS on 90+/-7days after admission, NIHSS/mRS compared with admission. 5)Dimention of ischemic lesion on MRI FLAIR imaging on 90+/-7days after admission. 6)Episode of delirium on 1day, 2days, 3days, 4days and 7days after admission 7)Other adverse events	—

Measure

Time frame

1)mRS on discharge 2)NIHSS on 7+/-1days after admission, NIHSS compared with admission. 3)NIHSS/mRS on 30+/-4days after admission, NIHSS/mRS compared with admission. 4)NIHSS/mRS on 90+/-7days after admission, NIHSS/mRS compared with admission. 5)Dimention of ischemic lesion on MRI FLAIR imaging on 90+/-7days after admission. 6)Episode of delirium on 1day, 2days, 3days, 4days and 7days after admission 7)Other adverse events

—

Countries

Japan

Contacts

Public ContactJun-ichiro Shimada

Chiba Cardiovascular Center Department of Neurology

j-shimada@chiba-u.jp0436-88-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026